Crinetics Pharmaceuticals Statistics
Share Statistics
Crinetics Pharmaceuticals has 93.68M
shares outstanding. The number of shares has increased by 17.99%
in one year.
| Shares Outstanding | 93.68M |
| Shares Change (YoY) | 17.99% |
| Shares Change (QoQ) | 0.34% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 47,476 |
| FTD / Avg. Volume | 4.64% |
Short Selling Information
The latest short interest is 9.84M, so 10.5% of the outstanding
shares have been sold short.
| Short Interest | 9.84M |
| Short % of Shares Out | 10.5% |
| Short % of Float | 11.96% |
| Short Ratio (days to cover) | 12.49 |
Valuation Ratios
The PE ratio is -13.84 and the forward
PE ratio is -7.41.
Crinetics Pharmaceuticals's PEG ratio is
0.
| PE Ratio | -13.84 |
| Forward PE | -7.41 |
| PS Ratio | 3975.39 |
| Forward PS | 2.4 |
| PB Ratio | 3.12 |
| P/FCF Ratio | -17.97 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Crinetics Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 23.04,
with a Debt / Equity ratio of 0.04.
| Current Ratio | 23.04 |
| Quick Ratio | 23.04 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | -0.15 |
| Debt / FCF | -0.23 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $2,377.57 |
| Profits Per Employee | $-682,855.84 |
| Employee Count | 437 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -37.18% in the
last 52 weeks. The beta is 0.32, so Crinetics Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 0.32 |
| 52-Week Price Change | -37.18% |
| 50-Day Moving Average | 32.25 |
| 200-Day Moving Average | 45.66 |
| Relative Strength Index (RSI) | 46.66 |
| Average Volume (20 Days) | 1,022,737 |
Income Statement
In the last 12 months, Crinetics Pharmaceuticals had revenue of 1.04M
and earned -298.41M
in profits. Earnings per share was -3.69.
| Revenue | 1.04M |
| Gross Profit | -1.75M |
| Operating Income | -338.85M |
| Net Income | -298.41M |
| EBITDA | -338.85M |
| EBIT | -338.85M |
| Earnings Per Share (EPS) | -3.69 |
Full Income StatementBalance Sheet
The company has 264.55M in cash and 51.72M in
debt, giving a net cash position of 212.82M.
| Cash & Cash Equivalents | 264.55M |
| Total Debt | 51.72M |
| Net Cash | 212.82M |
| Retained Earnings | -952.11M |
| Total Assets | 1.43B |
| Working Capital | 1.32B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -225.97M
and capital expenditures -3.84M, giving a free cash flow of -229.81M.
| Operating Cash Flow | -225.97M |
| Capital Expenditures | -3.84M |
| Free Cash Flow | -229.81M |
| FCF Per Share | -2.84 |
Full Cash Flow StatementMargins
Gross margin is -168.05%, with operating and profit margins of -32613.47% and -28720.69%.
| Gross Margin | -168.05% |
| Operating Margin | -32613.47% |
| Pretax Margin | -28720.69% |
| Profit Margin | -28720.69% |
| EBITDA Margin | -32613.47% |
| EBIT Margin | -32613.47% |
| FCF Margin | -22118.77% |
